Mary T. Szela
Independent DirectorMs. Mary T. Szela, M.B.A. B.S.N., served as Independent Director at Averin Capital Acquisition Corp. since February 19, 2026 until October 16, 2026. She is an Independent Director of Absci Corporation from July 7, 2025. She is Director of LARONDE, Inc. from February 2024. Ms. Szela served as an Independent Director at Prometheus Biosciences, Inc. since February 17, 2021 until June 16, 2023. Ms. Szela had been a Director of Alimera Sciences, Inc. since June 19, 2018 until June 15, 2021. Ms. Szela has been an Independent Director of Kura Oncology, Inc. since November 6, 2018. She serves as a Director of Senda Biosciences, Inc. She serves as Independent Director of Omega Therapeutics, Inc since June 2019. She serves as Chief Executive Officer, President and Director of TriSalus Life Sciences, Inc. since January 2018. From January 2016 to November 2016, Ms. Szela served as Chief Executive Officer and a director of Aegerion Pharmaceuticals, Incorporated. She served on Board of Suneva Medical, Inc. Ms. Szela served as Chief Executive Officer of Novelion Therapeutics, from January 2016 to November 2017, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Additionally, she secured the approval, registration and launch of lomitapide in Japan, oversaw the European filing for metreleptin and built a clinical development platform to treat multiple diseases using leptin hormone replacement therapy. Prior to Novelion, Ms. Szela was Chief Executive Officer of Melinta Therapeutics, from January 2013 to August 2015, leading the company’s revitalization effort, accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). from April 2013 to August 2015. Ms. Szela has experience as an executive in the biotechnology and pharmaceutical industry. She was a Director of Receptos Inc. from June 2014 to July 2015, Novo Nordisk from March 2014 to March 2017 and Novelion Therapeutics. She served as Director of Macrolide Pharmaceuticals, from March 2018 to July 2019. From 1987 to 2012, Ms. Szela held progressive leadership roles with Abbott Laboratories, a multinational medical devices and health care company, including Vice President, U.S. Commercial Operations, President of U.S. Pharmaceuticals and culminating as Senior Vice President of Global Strategic Market and Services. Ms. Szela worked for the University of Illinois Hospital. Ms. Szela served as an Independent Director at Coherus BioSciences, Inc. since July 2014 until August 5, 2021. She earned an M.B.A. in Business and a B.S. in Nursing, both from the University of Illinois.
Positions
- Company NameKura Oncology, Inc.Stock CodeKURAPositionIndependent DirectorColleagues
- TETroy Edward WilsonChairman, CEO & President
- KFKathleen FordChief Operating Officer
- BTBrian T. PowlChief Commercial Officer
- JFJennifer FulkChief Financial Officer
- TDThomas DoyleSenior Vice President of Finance & Accounting
- KMKevan M. ShokatChairman of the Scientific Advisory Board
- TRThomas Robert MalleyIndependent Director
- CACarol A. SchaferIndependent Director
- Company NameTriSalus Life Sciences, Inc.Stock CodeTLSIPositionCEO, President & DirectorRelated SecuritiesColleagues
- MTMary T. SzelaCEO, President & Director
- MLMats L. WahlstromIndependent Chairman
- DBDavid B. PatienceChief Financial Officer
- RBRichard B. MarshakChief Commercial Officer
- AMAndrea MarassoVice President of Marketing
- JLJennifer L. StevensChief Regulatory, Quality and Therapeutics Officer
- KRKerry R. HicksIndependent Director
- DJDavid J. MatlinIndependent Director
- WJWilliam J. ValleIndependent Director
